Bone Metabolism Archive
Roux-en Y gastric bypass increased the likelihood of nonvertebral fractures, including hip, wrist, and pelvic fractures.
Researchers investigated the effects of growth hormone vs placebo, as well as the effects of sex steroid replacement therapy on bone mineral density in growth hormone-treated young adults with Prader-Willi syndrome who had attained adult height.
In this review, 2 independent investigators searched clinical trial databases for studies that evaluated the link between vitamin D supplements and bone health in adult patients with epilepsy.
Abatacept was superior at increasing bone mineral density in the femoral neck compared with other biologic disease-modifying antirheumatic drugs, and may offer good efficacy for improving BMD in rheumatoid arthritis.
Researchers showed that decreased L1 trabecular attenuation is associated with increased risk for future osteoporotic fractures in adult patients aged ≥65 years undergoing abdominopelvic CT scans for other indications.
Researchers compared the effects of combined metformin and COX-2 inhibitor therapy vs COX-2 therapy alone on joint replacement surgery rates.
Researchers observed detrimental effects of RYGB on bone turnover, mass, structure, and strength just 6 months postoperatively, and these effects persisted throughout the duration of the 12-month study.
The use of biologic disease-modifying antirheumatic drugs has no medium-term effect on the risk for spinal fractures among patients with ankylosing spondylitis.
Study assessed the effect of denosumab on bone mineral density and incident fractures in older adults with primary hyperparathyroidism who could not undergo or refused surgery.
A lower bone mineral density in the lumbar spine, femoral neck, and hip is associated with an increased risk for intracranial aneurysm.
Study showed that parathyroid hormone was a significant predictor of lumbar spine bone mineral density Z-score for pseudohypoparathyroidism 1B patients.
In postmenopausal women at high risk for fracture, treatment with romosozumab for 12 months, followed by alendronate, was associated with significantly fewer hip fractures than treatment with alendronate alone.
Increased odds of fractures in pediatric patients with asthma may be associated with systemic corticosteroid use, but not with inhaled corticosteroid use.
Study investigated the correlations between age and body composition with trabecular morphology in a cohort of healthy girls age 9 to 18.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
New findings do not support routine vitamin D and calcium supplementation in community-dwelling older adults for lowering the incidence of osteoporosis-related fractures.
Researchers conducted a long-term follow-up study to determine whether BMD loss, osteoporosis, and fractures were successfully treated or prevented in an urban population of patients with epilepsy and reduced bone density.
Teriparatide is associated with a lower risk for new vertebral and clinical fractures compared with risedronate in post-menopausal women being treated for severe osteoporosis.
Bone mineral density was evaluated annually of the lumbar spine and femoral neck.
The association between alendronate use and nonvertebral fracture was strongest in patients who received high doses of glucocorticoid.
In a randomized multidose trial, single doses of zoledronate (1-5 mg) prolonged antiresorptive activity ≥3 years in postmenopausal women with osteopenia.
The prevalence of sarcopenia — particularly in combination with ostepenia — increases with age, and sarcopenic obesity may be underrecognized, despite its impact in patients with rheumatic diseases.
Risk of vertebral fractures may be increased with discontinuation of denosumab therapy.
The task force recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women ≥65 years and postmenopausal women.
While parathyroid hormone levels may be used to anticipate calcium decline, a "normal" PTH level does not always correctly predict postoperative calcium level.
The USPSTF commissioned a systematic evidence review on vitamin D, calcium, and combined supplementation for the primary prevention of fractures in community-dwelling adults.
Type 2 diabetes is significantly underdiagnosed and undertreated in patients with rheumatoid arthritis.
Height gains "substantially outpaced" bone mineral content gains during childhood, potentially leading to increased fracture risk.
Both intensity of physical activity and time spent active can explain variability in femoral neck BMD in people with class III obesity.
A femoral stress index assessment evaluates fracture risk in children as effectively as femoral and total body bone mineral density.
In a double-blind multicenter study, researchers examined the safety and efficacy of burosumab for X-linked hypophosphatemia.
Both anxiety and depression scores are associated with low BMD.
Intermittent hypoxia in obstructive sleep apnea was found to decrease the chances of bone health decline in menopausal women.
A single bone mineral density measure and fracture history can predict long-term fracture risk in older women.
According to a study published in the Journal of Bone and Mineral Research, researchers hypothesized that serum K-Postn levels may be able to predict low-trauma fractures.
The effect of 1 year of cross-sex hormone therapy on bone mineral density was examined in transgender men and women.
Daily supplementation with B vitamins and folic acid does not affect fracture risk for women with preexisting CV disease.
Researchers examined the benefits and risks associated with delaying ART initiation to slow bone mineral density loss.
Bone mineral density of the femoral neck, a significant predictor of fracture risk, declined nearly twice as quickly in HIV-infected women compared with HIV-infected men.
Researchers conducted a systematic review of available literature to create a guide for optimal management of patients with type 2 diabetes and osteoporosis.
The FDA has requested data from 2 additional phase 3 clinical trials analyzing the safety and effectiveness of romosozumab, Amgen, Inc. and UCB's joint osteoporosis drug.
Changes in bone mineral density at 1 year were similar in the immediate and delayed ART groups.
After parathyroidectomy, morbidity and mortality rates were considerably higher in patients with secondary and tertiary vs primary hyperparathyroidism.
Daytime sleepiness and poor quality of sleep affect recurrent fall risk in the elderly.
Hand pain, disability, and stiffness were common in long-term type 1 diabetes.
Healthy middle-age patients who took colecalciferol did not have a reduced risk for fall or fracture.
Twenty minutes per day of walking or bicycling were associated with a lower rate of fracture.
Participants who lost between 5% and 10% or more than 10% of their body weight slowed knee joint degeneration, compared to those who maintained their current weight.
A randomized double-blind trial examined the safety and efficacy of ertugliflozin plus metformin for inadequately controlled type 2 diabetes.
A 2.5 times higher fracture risk was noted among elderly patients taking sleeping pills.
Long-term denosumab increased bone mineral density in postmenopausal women.
The female athlete triad includes low energy availability, menstrual dysfunction, and low bone density.
After 1 year of therapy, men who underwent testosterone therapy experienced improvement in bone mineral density and mood.
An update to the 2008 ACP osteoporosis treatment guidelines focuses on treating low bone density and osteoporosis in an effort to prevent fractures.
Tuberculosis was identified as an independent risk factor associated with incident osteoporosis.
Women who had taken oral contraceptives for more than 5 years had the lowest risk for fracture.
A review of osteoporosis diagnosis, treatment, and management in both men and women.
At 6 months of exercise intervention, physical performance test scores increased 21% in the combination exercise group, while scores in the control group remained largely the same.
Eighty-four percent of survey respondents did not undergo osteoporosis pharmacotherapy following an osteoporosis-related fracture.
Tymlos approval was based on the results of the ACTIVE and ACTIVExtension trials.
Investigators examined an 83-year-old male patient who developed severe hypocalcemia induced by denosumab.
Bone ultrasonography is able to detect tenofovir-induced bone loss in patients with HIV.
After 24 months, bone mineral density was statistically different from baseline.
Moderate-to-vigorous physical activity was found to be an independent predictor of bone strength in adolescents.
The most common adverse events associated with long-term denosumab use were back, musculoskeletal, or extremity pain, hypercholesterolemia, and cystis.
The most important predictor for use of osteoporosis care was receiving primary care services within 6 months following hip fracture.
Findings in postmenopausal women with T2DM; correlations prominent in those with higher 25(OH)D
Researchers compared the efficacy of dual-energy x-ray absorptiometry with lateral x-ray in assessing vertebral fractures.
Fragility fracture risk increased with older age and decreased with higher bone mineral density in patients with type 1 diabetes.
Using dual-energy X-ray absorptiometry for bone age assessment complements traditional radiologic assessment.
Researchers evaluated trabecular bone scores in more than 100 women during either "legs up" or "legs down" dual energy x-ray absorptiometry scans.
Neither DXA-visceral adipose tissue nor android-gynoid fat mass ratios were associated with atherosclerotic cardiovascular disease events.
The Bone Health TeleECHO Clinic helps telementor healthcare professionals and improves osteoporosis care in underserved communities.
Total hip BMD was associated with heart failure risk in black and non-black men, with an interaction by race.
Testosterone treatment improved both bone mineral density and strength in older men.
The effects of repeat doses of antenatal betamethasone were assessed in 185 eligible pediatric patients.
Researchers found that female patients recovering from critical illness respond better to anti-fracture therapy for bone mineral density loss prevention compared with men.
Disease burden associated with hypophosphatasia was analyzed in a population of patients utilizing electronic medical records.
Study examines the predictive value for vertebral fractures of bone mineral density and bone turnover markers after a 5-year drug holiday.
The long-term effects of several hepatitis virus antivirals on various aspects of bone metabolism are unclear.
The risk of developing fracture in postmenopausal women with osteoporosis who discontinued bisphosphonate therapy was evaluated in a retrospective study.
The trabecular bone score may provides an acute, albeit indirect, measurement of bone quality in patients with type 2 diabetes.
Data were collected from the Osteoarthritis Initiative to examine the relationship between knee osteoarthritis and hypertension.
Patients with rheumatoid arthritis (RA) were evaluated at a specialized clinic to determine the relationship between knee osteoarthritis and elevated Disease Activity Scores (DAS28).
Patients taking tenofovir should aim to maximize the phosphorous in their diet.
Ankle fractures presented similar mortality rates between men and women, while other types of fractures had higher mortality rates among men.
Researchers examined the nonvertebral fracture risk in adults with obesity who underwent Roux-en-Y gastric bypass vs adjustable gastric banding.
Incident falls were linked with total testosterone and bioavailable levels of testosterone after adjusting for age and prevalent falls.
Two distinct time trends were observed in initiation of oral bisphosphonates in women after the 2008 updated osteoporosis treatment guidelines.
Younger survivors of thyroid cancer are at increased risk for certain types of health problems later in life.
Patients with psoriatic arthritis or psoriasis had an increased prevalence of osteoporosis risk factors.
Bone Index announced that the Food and Drug Administration (FDA) has granted clearance for the second generation Bindex device model to aid in the diagnosis of osteoporosis.
A prospective cohort study in 66 patients with end-stage renal disease was conducted to determine the link between renal and coronary heart diseases.
Cardiovascular disease, stroke, diabetes, hip and knee replacements, and both behavioral and mental disorders were also more common in the Alzheimer's disease cohort.
Etelcalcetide shows promise for reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
According to the National Cancer Institute, there are not enough available data to establish whether taking vitamin D can prevent cancer.
Less frequent dosing with zoledronic acid does not increase fracture risk in patients with bone metastases.
The association between risk for hip fracture and diabetes was attenuated after accounting for mortality risk.
For patients with type 2 diabetes, long-term use of dipeptidyl peptidase-4 (DPP-4) inhibitors is not associated with fracture risk.
Lorraine Fitzpatrick, MD, discusses updated results from the ACTIVE phase 3 clinical trial.
Endocrinology Advisor Articles
- Predictors of Success for Insulin-to-Liraglutide Switch for Type 2 Diabetes
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Pre-Pregnancy Programs May Improve Outcomes in Women With Type 2 Diabetes
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- IV Fluid Infusion Rates Do Not Affect Pediatric DKA Neurologic Outcomes
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Psychiatric Morbidity Decreased After Assisted Reproductive Technology Treatment
- Fenofibrate Improves Cholesterol Levels in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk